Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology
November 30 2018 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in hematology and oncology, today
announced presentations of clinical and scientific data related to
Peripheral T-cell Lymphoma (PTCL) and EVOMELA® (melphalan) at
the 60th Annual Meeting of the American Society of Hematology (ASH)
being held in San Diego, California, from December 1-4, 2018.
For more information about the ASH annual meeting and for a
complete list of abstracts, please refer to the conference website
at https://ash.confex.com/ash/2018/webprogram/start.html.
The following posters will be presented at the ASH meeting:
- Management of Mucositis with Use of
Leucovorin as Adjunct to Pralatrexate in Treatment of Patients with
Hematological Malignancies including of Peripheral and Cutaneous
T-Cell Lymphomas-Results from a Prospective Multicenter Phase 2
Clinical Trial. Poster 2910; Presented on Sunday, Dec 2, 6:00
PM-8:00 PM, Hall GH
- Role of Single Agent and Combination
Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell
Lymphoma: Results from the Complete Registry. Poster 2926;
Presented on Sunday, Dec 2, 6:00 PM-8:00 PM, Hall GH
- Safety and Efficacy of Evomela in
Myeloma Autotransplants; Poster 3446; Presented on Sunday, Dec 2,
6:00 PM-8:00 PM, Hall GH
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in hematology and oncology. Spectrum
currently markets seven hematology/oncology drugs and has an
advanced stage pipeline that has the potential to transform the
company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available at
www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® and EVOMELA® are registered
trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181130005045/en/
Spectrum PharmaceuticalsShiv KapoorVice President, Strategic
Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024